undamentalytics Newsletter
Sign in

Crispr Therapeutics AG income statement

In fiscal 2025, Crispr Therapeutics AG reported revenue of $3.5m, down 90.6% on the year before, operating income of −$665m (a -18933.6% margin) and net income of −$582m, or −$6.47 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue054132901915137137425
Research and development134270114179221341462387310285291
General and administrative13313648638610010276737471
Operating income−26−68−65−15947−354374−673−223−467−665−532
Income before tax−26−23−67−16467−348380−651−151−363−578−454
Income tax0021012−03442
Net income−26−23−68−16567−349378−650−154−366−582−456
Diluted EPS−$5.06−$1.89−$1.71−$3.44$1.17−$5.29$4.70−$8.36−$1.94−$4.34−$6.47−$4.74
Diluted shares (average)5m12m40m48m57m66m80m78m79m84m90m96m
EBITDA−26−67−62−15551−345391−649−203−447−645−514

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ABEO vs CRSPCRSP vs JANXCRSP vs STOK

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Crispr Therapeutics AG's SEC filings (10-K and 10-Q), retrieved November 3, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Crispr Therapeutics AG.